6533b858fe1ef96bd12b5793
RESEARCH PRODUCT
Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19
Jeffrey I. WeitzSeyed Hossein HosseiniGregory PiazzaDavid JiménezGregory Y.h. LipManuel MonrealSahil A. ParikhBehnood BikdeliMary CushmanAjay J. KirtaneMichelle SholzbergSepehr JamalkhaniParham SadeghipourAzita Hajhossein TalasazAzin GheymatiGregg W. StoneBeverley J. HuntHarlan M. KrumholzMaryam AghakouchakzadehBenjamin W. Van TassellSamuel Z. GoldhaberHamid AriannejadElaheh Kordzadeh-kermaniStavros KonstantinidesJean M. ConnorsHessam KakavandJohn W. Eikelboomsubject
medicine.medical_specialtyCoronavirus disease 2019 (COVID-19)business.industrymedicine.drug_classAnticoagulantState of the art review030204 cardiovascular system & hematologymedicine.diseaseThrombosislaw.inventionClinical trial03 medical and health sciences0302 clinical medicinePharmacotherapyRandomized controlled triallawAntithromboticMedicine030212 general & internal medicineCardiology and Cardiovascular MedicinebusinessIntensive care medicinedescription
Endothelial injury and microvascular/macrovascular thrombosis are common pathophysiological features of coronavirus disease-2019 (COVID-19). However, the optimal thromboprophylactic regimens remain unknown across the spectrum of illness severity of COVID-19. A variety of antithrombotic agents, doses, and durations of therapy are being assessed in ongoing randomized controlled trials (RCTs) that focus on outpatients, hospitalized patients in medical wards, and patients critically ill with COVID-19. This paper provides a perspective of the ongoing or completed RCTs related to antithrombotic strategies used in COVID-19, the opportunities and challenges for the clinical trial enterprise, and areas of existing knowledge, as well as data gaps that may motivate the design of future RCTs.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2021-04-01 | Journal of the American College of Cardiology |